Virtual Symposium and Case Simulation *NEW*: Managing LDL-C to Reduce ASCVD Risk: Recent Advancements and Strategies to Optimize Patient Outcomes

ACTIVITY TITLE

Virtual Symposium and Case Simulation: Managing LDL-C to Reduce ASCVD Risk: Recent Advancements and Strategies to Optimize Patient Outcomes

ACTIVITY FORMAT

Virtual Symposium and Case Simulation

PROGRAM DESCRIPTION

In this symposium, faculty will overview the management of hypercholesterolemia to reduce the risk of adverse atherosclerotic cardiovascular disease (ASCVD) events, including how to identify patients with statin intolerance or with residual risk despite maximized statin therapy, as well as current management of elevated cholesterol with statin and non-statin therapies according to the updated guidelines. In addition, the symposium will summarize the evidence on the use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, and emerging cholesterol-lowering therapies. Challenges with access to newer therapies and appropriate resources to address this issue will also be reviewed.

During the activity, case-based, patient simulation technology will be utilized to provide learners with the opportunity to explore different decision paths and get immediate feedback on their treatment decisions, allowing for enhanced competence in the individualization of therapy for patients at-risk for ASCVD.

Learners are also provided online access and a PDF copy of a Rapid Review Pocket Guide: Guidance on Cholesterol Management.

ESTIMATED TIME TO COMPLETE: 75 minutes

RELEASE DATE: January 17, 2020

EXPIRATION DATE: January 17, 2021

EDUCATIONAL GRANT SUPPORT

This educational activity is multi-supported by educational grants from Sanofi US and Regeneron Pharmaceuticals, The Medicines Company, and Esperion.

INTENDED AUDIENCE

This activity is designed for US-based endocrinologists, cardiologists, lipidologists, diabetologists, gastroenterologists, hepatologists, PAs, registered nurses, and NPs

EDUCATIONAL OBJECTIVES

After completing this activity, the participant should be better able to:

• Identify patients with elevated LDL-C who are statin intolerant based on past medical and familial history, adverse effects of statins, and recommended definitions and diagnostic guidelines
• List new and emerging treatment options for ASCVD prevention or management in high-risk patients with hypercholesterolemia
• Develop individualized treatment regimens for prevention of adverse cardiovascular events in high-risk patients with elevated LDL-C and comorbidities based on the current ACC/AHA guidelines and evidence about the safety and efficacy of non-statin therapies
• Employ strategies and resources designed to improve patients’ access to new treatment options for hypercholesterolemia that may minimize risk of adverse cardiovascular events

FACULTY

Christie M. Ballantyne, MD (Chair)

• Professor of Medicine
• Chief, Section of Cardiovascular Research
• Chief, Section of Cardiology
• Department of Medicine, Baylor College of Medicine
• Director, Center for Cardiovascular Disease Prevention
• Baylor College of Medicine
• Methodist DeBakey Heart Center
• Houston, TX

Leslie Cho, MD

• Professor of Medicine
• Section Head, Preventive Cardiology and Rehabilitation
• Cleveland Clinic
• Cleveland, OH

JOINT ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and CMHC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING MEDICAL EDUCATION

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTINUING NURSING EDUCATION

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.2 contact hours. Designated for 0.5 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.

PHARMACIST ACCREDITATION STATEMENT

Postgraduate Institute for Medicine designates this continuing education activity for 1.25 contact hour(s) (.125 CEUs) of the Accreditation Council for Pharmacy Education.

This is an application-based activity. Universal Activity Numbers (UAN): JA4008162-9999-19-1026-H01-P.

Upon completing the post-survey and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4-6 weeks.

DIETICIAN ACCREDITATION STATEMENT

Postgraduate Institute for Medicine (CDR Provider #3631) is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). CDR Credentialed Practitioners will receive 1.5 Continuing Professional Education units (CPEUs) for completion of this activity.

This is a Level II activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COO they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty

Dr. Ballantyne discloses the following:

• Grant/Research Support: All significant. (All paid to institution, not individual): Abbott Diagnostic, Akcea, Amgen, Esperion, Novartis, Regeneron, Roche Diagnostic, Sanofi-Synthelabo, NIH, AHA, ADA.
• Consultant: Abbott Diagnostics, Akcea, Amarin, Amgen, AstraZeneca*, Boehringer lngelheim, Denka Seiken, Esperion, Intercept, Janssen, Matinas BioPharma Inc, Merck*, Novartis, Novo Nordisk, Regeneron, Roche Diagnostic, Sanofi-Synthelabo*

*Significant where noted (>$10,000); remainder modest (<$10,000).

Dr. Cho discloses the following:

• Consulting Fees: Amgen

Planners and Managers

The PIM planners and managers have nothing to disclose.

The CMHC planners and managers have nothing to disclose.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

METHOD OF PARTICIPATION & REQUEST FOR CREDIT

There are no fees for participating and receiving CME/CE credit for this activity. During the period January 17, 2020 through January 17, 2021, participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please complete the post-survey and evaluation. Upon completing, your certificate will be made available immediately.

Media: Internet

For questions about the accreditation of this activity, please visit www.pimed.com.

HARDWARE AND SOFTWARE REQUIREMENTS:

This online activity must be viewed with the latest version of Chrome, Firefox or Internet Explorer. If you do not have these browsers, you can download Chrome here, Firefox here and Internet Explorer here. Optimal viewing requires a broadband connection of at least 3 Mbps and a 1 GHz processor with 1 GB RAM.